MX2022008842A - Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. - Google Patents

Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.

Info

Publication number
MX2022008842A
MX2022008842A MX2022008842A MX2022008842A MX2022008842A MX 2022008842 A MX2022008842 A MX 2022008842A MX 2022008842 A MX2022008842 A MX 2022008842A MX 2022008842 A MX2022008842 A MX 2022008842A MX 2022008842 A MX2022008842 A MX 2022008842A
Authority
MX
Mexico
Prior art keywords
proteins
barrier function
treatment
therapeutic proteins
epithelial barrier
Prior art date
Application number
MX2022008842A
Other languages
English (en)
Inventor
Toshihiko Takeuchi
Ye Jin
Todd Zachary Desantis
Andrew Wonhee Han
Andrew Whitman Goodyear
Tarunmeet Gujral
Karim Dabbagh
Michi Izumi Willcoxon
Stefanie Banas
Original Assignee
Second Genome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Genome Inc filed Critical Second Genome Inc
Publication of MX2022008842A publication Critical patent/MX2022008842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)

Abstract

La descripción se refiere a proteínas terapéuticas y composiciones farmacéuticas que comprenden dichas proteínas, que son útiles en el tratamiento de diversas enfermedades humanas. En aspectos particulares, las proteínas terapéuticas descritas son útiles para tratar enfermedades inflamatorias gastrointestinales humanas y afecciones gastrointestinales asociadas con la disminución de la función o integridad de la barrera de células epiteliales. Además, las proteínas terapéuticas descritas son útiles para tratar una enfermedad inflamatoria intestinal humana, incluyendo, entre otras, la enfermedad de Crohn y la colitis ulcerosa.
MX2022008842A 2017-04-07 2019-10-07 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. MX2022008842A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US201762611334P 2017-12-28 2017-12-28

Publications (1)

Publication Number Publication Date
MX2022008842A true MX2022008842A (es) 2022-08-02

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012051A MX2019012051A (es) 2017-04-07 2018-04-06 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX2022008842A MX2022008842A (es) 2017-04-07 2019-10-07 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019012051A MX2019012051A (es) 2017-04-07 2018-04-06 Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.

Country Status (12)

Country Link
US (3) US10251933B2 (es)
EP (1) EP3606542A4 (es)
JP (2) JP2020516615A (es)
KR (2) KR20230144097A (es)
CN (1) CN110769844A (es)
AU (2) AU2018248324B2 (es)
CA (1) CA3059354A1 (es)
IL (1) IL269853A (es)
MX (2) MX2019012051A (es)
SG (1) SG11201909334TA (es)
TW (1) TWI797116B (es)
WO (1) WO2018187682A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012051A (es) 2017-04-07 2020-02-12 Second Genome Inc Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2019195859A1 (en) * 2018-04-06 2019-10-10 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
AU2020332371A1 (en) * 2019-08-21 2022-03-03 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
ES2568938T3 (es) * 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
CN114984057A (zh) 2015-06-15 2022-09-02 4D制药研究有限公司 包含细菌菌株的组合物
MX2019012051A (es) 2017-04-07 2020-02-12 Second Genome Inc Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2018223051A1 (en) 2017-06-02 2018-12-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Also Published As

Publication number Publication date
AU2018248324A1 (en) 2019-10-31
US20240066095A1 (en) 2024-02-29
US11207376B2 (en) 2021-12-28
JP2024037834A (ja) 2024-03-19
US20180289770A1 (en) 2018-10-11
MX2019012051A (es) 2020-02-12
SG11201909334TA (en) 2019-11-28
KR20230144097A (ko) 2023-10-13
US20200148728A1 (en) 2020-05-14
CN110769844A (zh) 2020-02-07
IL269853A (en) 2019-11-28
KR20200003821A (ko) 2020-01-10
CA3059354A1 (en) 2018-10-11
JP2020516615A (ja) 2020-06-11
WO2018187682A1 (en) 2018-10-11
EP3606542A4 (en) 2021-01-20
TWI797116B (zh) 2023-04-01
AU2023202844A1 (en) 2023-07-06
EP3606542A1 (en) 2020-02-12
AU2018248324B2 (en) 2023-02-09
US10251933B2 (en) 2019-04-09
TW201841649A (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
TN2020000038A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2021009673A (es) Moduladores de ror-gamma.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
WO2019032662A8 (en) Clec9a binding agents and use thereof
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
WO2015112793A3 (en) Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IN2012DN02645A (es)
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MX2015004844A (es) Firmas geneticas de trastornos inflamatorios que se relacionan con el higado.
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2021002321A (es) Nuevos metodos.
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
EA201690659A1 (ru) Композиции аморфного магнийзамещенного фосфата кальция и их применение
MX2019014365A (es) Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.